Intra-Sana Laboratories
$291.3K 3,142 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Merck KGaA
Merck KGaA reported $290,562.45 across General Payments, Research, and Ownership to 101 physicians and teaching hospitals across 132 transactions.
- $290.6K Above-median payer
- All-tracks total
- 132 Below-median volume
- Transactions
- 101 Below-median reach
- Recipients
- +$119.1K
- General Payments vs PY2023
Merck KGaA reported $290,562.45 across all CMS Open Payments tracks (General + Research + Ownership) to 101 physicians and teaching hospitals in Program Year 2024 - ranking #900 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $285,731.84, averaging $2.9K per recipient.
How Merck KGaA's $290.6K all-tracks total breaks down
Merck KGaA's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
21/100
Total payments
F
13/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer merck-kgaa Merck KGaA
$290.6K · #900/1,925 · 0.0% industry · PY2024
- TOT $290.6K
- RANK #900
- SHARE 0.0%
- TXN 132
- RCP 101
- CAT 4
- GEN $285.7K
- ΔGEN +$119.1K
- TOP1 15.4%
- PY 2024
Volume peers
Nearest volume peer: Intra-Sana Laboratories ($291.3K)
Merck KGaA sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Merck KGaA's CMS-reported General Payments increased by $119.1K (+71.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: MERCK KGAAPY2023: MERCK KGAAPY2024: Merck KGaA. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $166,601.34
- PY2024
- $285,731.84
What the Data Shows for Merck KGaA
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Merck KGaA, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $170.1K, accounting for 59.5% of this company's General Payments and 39 transactions.
General Payment Breakdown by Type
Merck KGaA made 4 types of general payments. "Consulting Fee" is the largest category at $170.1K, 59.5% of General Payments.
Merck KGaA reports 4 general-payment categories - the top three are Consulting Fee (59.5%), Travel and Lodging (28.0%), and Compensation for Services Other Than Consulting (12.0%). The remaining 1 category make up 0.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Merck KGaA divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $170.1K | 39 | 59.5% |
| Travel and Lodging | $80.1K | 33 | 28.0% |
| Compensation for Services Other Than Consulting | $34.2K | 7 | 12.0% |
| Food and Beverage | $1.3K | 22 | 0.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $124,266.16 (43.5%) of $285,731.84 in this company's General Payments records across 40 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Merck KGaA
The five named recipients with the highest reported General Payments from this company
- 1
Jeremy Sugarman
$44,080.86 across 17 reported transactions
- 2
Leorah a Freeman
$22,055.61 across 6 reported transactions
- 3
Riley Bove
$20,450.00 across 4 reported transactions
- 4
Heidi J Crayton
$20,232.47 across 7 reported transactions
- 5
Jonathan Schoenfeld
$17,447.22 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Merck KGaA ranks #900 of 1,925 by total payments (top 47% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,237 of 1,838 by HHI (bottom 33% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Rivanna Medical, Inc : $51.3K total payments, HHI 604
- CIVCO Medical Instruments : $25.0K total payments, HHI 601
- Rapid Medical Ltd : $271.8K total payments, HHI 600
- Getinge USA Sales, LLC : $462.9K total payments, HHI 589
- Henry Schein One, LLC : $39.9K total payments, HHI 589
- Nsk America Corporation : $1.2K total payments, HHI 588
- Merck KGaA (this company) : $285.7K total payments, HHI 587
- CONMED Corporation : $945.9K total payments, HHI 586
- Accuray Incorporated : $113.0K total payments, HHI 584
- IlluminOss Medical, Inc. : $168.9K total payments, HHI 583
- Medacta USA, Inc. : $8.4M total payments, HHI 583
- Kub Technologies Inc. : $14.7K total payments, HHI 583
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Merck KGaA's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Merck KGaA.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Merck KGaA.
Showing 6 of 1,924 companies with CMS-reported payment data.
Septodont Inc.
$289.4K 1,604 recipients
Compare payment profiles
Exo Imaging, Inc.
$292.7K 175 recipients
Compare payment profiles
Farallon Surgical, LLC
$288.4K 6 recipients
Compare payment profiles
Evoke Pharma, Inc.
$292.8K 3,417 recipients
Compare payment profiles
Nexxt Spine LLC
$292.8K 358 recipients
Compare payment profiles
Put this to use
Merck KGaA ranks #900 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Merck KGaA. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.